Ashland Global Hlds

Ashland, Inc. engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. It operates through the following segments: Life Sciences, Personal Care, Special Additives, and Intermediates. The company was founded in 1924 and is headquartered in Wilmington, DE.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Ashland Global Hlds faces Q2 challenges, eyes pharma growth

Ashland Global Hlds faced challenges in Q2 2023 from global uncertainties and destocking, impacting margins and earnings, while showing strength in the pharma and Life Sciences segments.
The company's strategic focus on M&A in growth areas and ending destocking actions in key segments present opportunities for revenue growth and value creation.
Despite challenges, Ashland's performance reflects resilience and strategic decision-making, with a positive outlook for cash flow improvement and long-term growth.
Investors should monitor the company's progress in addressing challenges, leveraging strengths, and capitalizing on opportunities to drive sustainable financial performance.

Ashland Global Hlds faces destocking challenges but emphasizes resilience and growth

Ashland Global Hlds faced challenges from customer destocking, leading to a decline in sales and adjusted EBITDA, but demonstrated resilience and strength in managing mix improvements and margins.
The company remains focused on innovation, growth opportunities, and market confidence, with investments in core assets and new technologies continuing despite market challenges.
Opportunities lie in new product initiatives, global expansion, and capacity additions in key technologies, positioning Ashland Global Hlds for future growth and success.
Despite short-term challenges, Ashland Global Hlds maintains a strategic outlook, emphasizing long-term strategies, market confidence, and a commitment to driving growth through innovation.

Ashland Global Hlds faces challenges but targets growth opportunities

Ashland Global Hlds faced challenges in Q4 and anticipates uncertainties in 2024 but remains focused on long-term growth opportunities.
The company is optimizing its portfolio, targeting new growth drivers, and managing costs effectively to navigate current market conditions.
Despite near-term challenges, Ashland is resilient and committed to maximizing upside potential while minimizing downside risks.
Management's emphasis on proactive inventory control, cost management, and strategic priorities underscores their commitment to long-term success.

Ashland Global Hlds reports mixed Q1 results, focuses on long-term growth

Ashland Global Hlds reported mixed Q1 results with sales decline and EBITDA decrease, focusing on long-term growth strategies and shareholder value creation.
Challenges include lower demand in key units, compensation adjustments, market dynamics, and cost management considerations, while opportunities lie in M&A, innovation, and market expansion.
Stability in certain business segments and strategic initiatives to optimize operations provide a foundation for future growth and profitability amidst current challenges.
Overall, Ashland's performance reflects a balancing act between short-term setbacks and long-term strategic positioning for sustainable growth and market competitiveness.

Ashland Global Hlds beats Q2 expectations, eyes growth opportunities

Ashland Global Hlds demonstrated resilience in Q2 2024, exceeding EBITDA outlook and focusing on strategic growth.
Despite challenges in pricing and market dynamics, the company maintains a strong financial position and growth focus.
Opportunities lie in innovation, segment growth, and EBITDA normalization above 2021 levels.
The company's performance reflects a balance of challenges, strengths, and a proactive approach to future growth.

Ashland reports solid Q4 results, eyes global growth opportunities

Ashland Global Hlds (ASH) delivered a resilient performance in Q4 2024, with sales and adjusted EBITDA showing positive growth trends.
Strategic priorities for fiscal year 2025 aim to address challenges, capitalize on opportunities, and drive profitable growth for the company.
Despite near-term uncertainties, Ashland remains optimistic about its long-term prospects and ability to navigate evolving market conditions.

Ashland Global Hlds reports Q1 sales decline, focuses on growth

Q1 performance for Ashland Global Hlds showed a decline in sales and EBITDA due to portfolio actions.
Strategic priorities focus on cost-saving, globalization, and innovation for long-term growth.
Challenges include trade policy impacts, currency fluctuations, and concerns in China and Europe.
Opportunities exist in executing strategic initiatives and monitoring market dynamics for growth.

Ashland Global Hlds reports Q2 sales decline, focuses on innovation

Ashland Global Hlds faces challenges from global trade dynamics and core business declines but is leveraging strengths in Life Sciences and Personal Care segments. The company is focused on cost savings, innovation, and market opportunities to drive growth. Stabilization efforts have shown positive results, with a revised outlook for sales and adjusted EBITDA.

Ashland Global Hlds reports stable Q3 performance amidst segment challenges

Ashland Global Hlds' Q3 2025 earnings call highlighted stable performance, challenges in segment sales, and a focus on cost savings. The company's strategic direction, operational optimization efforts, and outlook for fiscal year 2025 were key discussion points. Analysts raised questions about restructuring savings, market dynamics, and innovation's impact on EBITDA.

Ashland Global Hlds reports Q4 challenges but sees growth opportunities

Ashland Global Hlds' Q4 2025 performance reflects challenges in sales but progress in margin expansion and cost savings through transformation efforts. The company's strategic focus on portfolio optimization, material mix shift, and network optimization presents opportunities for future growth and profitability. Despite external uncertainties, Ashland remains confident in its strategy execution, innovation focus, and ability to navigate market challenges for sustained competitiveness.

Ashland Global Hlds reports mixed Q1 results, focuses on innovation

Ashland Global Hlds showcased steady performance with a focus on innovation and operational enhancements. Executives addressed market conditions, demand trends, and strategic priorities during the call. Company's commitment to portfolio optimization and productivity improvements underlines a path for profitable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ashland, Inc. is an additives and specialty ingredients company, which engages in the provision of architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical products. It operates through the following segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment is involved in pharmaceuticals, nutrition, nutraceuticals, agricultural chemicals, diagnostic films, and fine chemicals. The Personal Care segment consists of biofunctionals, microbial protectants, skin care, sun care, oral care, hair care, and household solutions. The Specialty Additives segment focuses on rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive, and various industrial markets. The Intermediates segment refers to production of 1,4 butanediol and related derivatives, including n-methylpyrrolidone. The company was founded in 1924 and is headquartered in Wilmington, DE.